Howyda Ebrahim1, Amany Nassar1, Mariam Mohammed Mousa2, Elsayed Khater1,3. 1. Drs. Ebrahim, Nassar and Khater are with the Faculty of Medicine at Zagazig University in Zagazig, Egypt. 2. Dr. Mousa is with the Faculty of Medicine at Omar Al-Mukhtar University in Al Bayda, Libya. 3. Dr. Khater is an assistant professor of dermatology in Faculty of Medicine at Zagazig University in Egypt.
Abstract
Background: The current treatments of Facial hyperhidrosis (FH) are often limited and are associated with many adverse effects. Objective: The objective was to study the efficacy and safety of botulinum toxin-A delivery by microneedling versus its intradermal injection in the treatment of FH. Forty-two patients with FH were subjected to microneedling (Mn) followed by topical application of BTX-A on one side of the face and intra-dermal injection of BTX-A on the other side. Two sessions were performed at two week intervals. The assessment tools were Hyperhidrosis Disease Severity Scale (HDSS), the Dermatology Life Quality Index (DLQI), and patient satisfaction. Results: A score of one of HDSS was achieved in 85.7 percent of patients on the intradermally injected side versus 83.3 percent on the microneedling side (P=0.76%). Most of the patients on the injection side responded with the first session while the microneedling side responded with the second one (P<0.001). The DLQI was highly significant on both sides post-treatment (P<0.001). The side effects were mild in the form of pain on the intradermally injected sides, and mild transient erythema on the microneedling side. The microneedling side showed higher patient satisfaction compared to the intradermally injected side. Conclusion: Both techniques were safe and effective in controlling the FH. Microneedling delivery of BTX-A was less painful and had higher patient satisfaction.
Background: The current treatments of Facial hyperhidrosis (FH) are often limited and are associated with many adverse effects. Objective: The objective was to study the efficacy and safety of botulinum toxin-A delivery by microneedling versus its intradermal injection in the treatment of FH. Forty-two patients with FH were subjected to microneedling (Mn) followed by topical application of BTX-A on one side of the face and intra-dermal injection of BTX-A on the other side. Two sessions were performed at two week intervals. The assessment tools were Hyperhidrosis Disease Severity Scale (HDSS), the Dermatology Life Quality Index (DLQI), and patient satisfaction. Results: A score of one of HDSS was achieved in 85.7 percent of patients on the intradermally injected side versus 83.3 percent on the microneedling side (P=0.76%). Most of the patients on the injection side responded with the first session while the microneedling side responded with the second one (P<0.001). The DLQI was highly significant on both sides post-treatment (P<0.001). The side effects were mild in the form of pain on the intradermally injected sides, and mild transient erythema on the microneedling side. The microneedling side showed higher patient satisfaction compared to the intradermally injected side. Conclusion: Both techniques were safe and effective in controlling the FH. Microneedling delivery of BTX-A was less painful and had higher patient satisfaction.
Authors: Erica Nishida Hasimoto; Daniele Cristina Cataneo; Tarcísio Albertin Dos Reis; Antonio José Maria Cataneo Journal: J Bras Pneumol Date: 2018-07-30 Impact factor: 2.624
Authors: Doha Obed; Mustafa Salim; Alperen S Bingoel; Thurid R Hofmann; Peter M Vogt; Nicco Krezdorn Journal: Aesthetic Plast Surg Date: 2021-02-22 Impact factor: 2.326